Related Experiment Videos

Down regulation of Qa gene expression on drug-modified tumor cells

E Leroy1, D Lattuada, C Casnici

  • 1Department of Pharmacology, School of Medicine, University of Milan, Italy.

Tumori
|December 31, 1993
PubMed
Abstract

Insights

Treatment with 5-(3-3'-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) decreases Qa2 molecule expression on L1210 mouse leukemia cells. This finding suggests Qa antigens may influence tumor cell tolerance or rejection in syngeneic hosts.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Mouse leukemia L1210 enhances immunogenicity after in vivo 5-(3-3 -dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) treatment.
  • Transformed cells can elicit a cell-mediated response leading to rejection and resistance against subsequent tumor cell injection.
  • L1210 cells express H-2 class I molecules, and DTIC treatment does not alter their expression, making it a suitable model for studying nonclassical class I antigens like Qa2 glycoproteins.

Purpose of the Study:

  • To investigate the role of nonclassical class I antigens, specifically Qa2 glycoproteins, in tumorigenicity.
  • To determine the effect of DTIC treatment on Qa antigen expression in L1210 leukemia cells.

Main Methods:

  • Cloned L1210 cells were treated with DTIC.
  • Expression of H-2D and Qa antigens was analyzed on four clones before and after xenogenization with DTIC.
  • Techniques included radioimmunoassay, immunofluorescent staining, FACS, and 2D-gel electrophoresis.

Main Results:

  • A significant decrease in Qa2 molecule expression was observed after DTIC treatment.
  • This reduction was confirmed by multiple analytical methods including FACS and 2D-gel analysis.

Conclusions:

  • DTIC treatment leads to a substantial decrease in Qa2 molecule expression on L1210 cells.
  • The presence or absence of Qa antigens on tumor cells may play a role in the development of tolerance or rejection in syngeneic animals.

Related Concept Videos